Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 7 of 7 citing Greenbaum: Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment.... (0.06 sec) 

GAD treatment and insulin secretion in recent-onset type 1 diabetes


J Ludvigsson, M Faresjo, M Hjorth, S … - The New England …, 2008 - nejm.highwire.org
Results Insulin secretion gradually decreased in both study groups. The study treatment had
no significant effect on change in fasting C-peptide level after 15 months (the primary end
point). Fasting C-peptide levels declined from baseline levels significantly less over 30 ...
Cited by 32 - Related articles - All 7 versions

Therapy with GAD in diabetes


J Ludvigsson - Diabetes/Metabolism Research and Reviews, 2009 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Related articles - All 2 versions

Treatment of patients with new onset Type 1 diabetes with a single course of anti- …


KC Herold, S Gitelman, C Greenbaum, J Puck, W … - Clinical Immunology, 2009 - Elsevier
Anti-CD3 mAbs may prolong β cell function up to 2 years in patients with new onset Type 1 diabetes
(T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was stopped after
10 subjects because of increased adverse events than in a previous trial related with ...
Cited by 2 - Related articles - All 2 versions

[CITATION] Challenges in developing endpoints for type 1 diabetes intervention studies …


S Cernea, I Raz, KC Herold, B … - Diabetes/ …, 2009 - John Wiley & Sons, Ltd. Chichester, …

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive …


E Vandemeulebroucke, B Keymeulen, K Decochez, I … - Diabetologia - Springer
Abstract Aims/hypothesis The aim of the study was to investigate the use of hyperglycaemic clamp
tests to identify individuals who will develop diabetes among insulinoma-associated
protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A+ FDRs) of type 1 diabetic ...

[CITATION] C-peptide an adequate endpoint in type 1 diabetes


J Ludvigsson - Diabetes/Metabolism Reviews - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...

Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from …


KM Dungan, JB Buse, RE Ratner - … /Metabolism Research and …, 2009 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Related articles - All 2 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google